CN108403780A - A kind of drug and preparation method thereof with hair tonic function - Google Patents
A kind of drug and preparation method thereof with hair tonic function Download PDFInfo
- Publication number
- CN108403780A CN108403780A CN201810303491.5A CN201810303491A CN108403780A CN 108403780 A CN108403780 A CN 108403780A CN 201810303491 A CN201810303491 A CN 201810303491A CN 108403780 A CN108403780 A CN 108403780A
- Authority
- CN
- China
- Prior art keywords
- parts
- hair
- drug
- pyrimidine
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of drugs with hair tonic function, it is made of the raw material of following portions by weight：2 10 parts of ginseng, 15 parts of cacumen biotae, 15 parts of Radix Astragali, 15 parts of the fruit of glossy privet, 15 parts of 2,4 di-amino-pyrimidine, 3 oxide.The present invention can not only hair growth, and the function of also dark hair, and persistent.
Description
Technical field
The invention belongs to pharmaceutical fields, are related to a kind of drug and preparation method thereof with hair tonic function.
Background technology
Alopecia is a kind of common disease disease.Currently, the major product of the alopecia chemicals for the treatment of is minoxidil solution
And finasteride tablet, chemicals easily rebound, side effect is big, high recurrence rate obtains disadvantage, and Chinese medicine preparation has action slowly, controls
More the low disadvantage of rate.
Invention content
The object of the present invention is to provide a kind of curative for effect, rapid-action, high hair tonic medicaments of cure rate.
In order to achieve the above object, the present invention uses following scheme：
A kind of drug with hair tonic function, is made of the raw material of following portions by weight：2-10 parts of ginseng, cacumen biotae 1-5
Part, 1-5 parts of Radix Astragali, 1-5 parts of the fruit of glossy privet, 2,4- 1-5 parts of di-amino-pyrimidine -3- oxides.
Preferably, the drug is made of the raw material of following portions by weight：4-8 parts of ginseng, 2-4 parts of cacumen biotae, Radix Astragali 2-5
Part, 2-4 parts of the fruit of glossy privet, 2,4- 2-4 parts of di-amino-pyrimidine -3- oxides.
Best, which is made of the raw material of following portions by weight：6 parts of ginseng, 3 parts of cacumen biotae, Radix Astragali 3
Part, 3 parts of the fruit of glossy privet, 2,4- 2 parts of di-amino-pyrimidine -3- oxides.
The preparation method of the drug includes the following steps：
1) ginseng, cacumen biotae, Radix Astragali, the fruit of glossy privet are taken, with 75% ethyl alcohol heating and refluxing extraction 2 times, 2 hours every time, filtering,
Merging filtrate is simultaneously concentrated into the clear cream that relative density is 1.1-1.2；
2) 2,4- di-amino-pyrimidine -3- oxides are dissolved with 95% ethyl alcohol, obtains solution；
3) solution of the clear cream of step 1), step 2) is merged, and is mixed with moisturizer, thickener, preservative, is made molten
Liquor.
The beneficial effects of the invention are as follows：
1) composition curative effect of the invention is better than 2% 2,4- di-amino-pyrimidine -3- oxide solutions.
2) ginseng in composition of the invention, cacumen biotae, Radix Astragali, the molecular compound of glossy privet can increase into 2,4- diaminos
The Transdermal absorption amount of yl pyrimidines -3- oxides.
3) after using the composition treatment of the present invention, recurrence rate is low；The white hair blackening of part population can be made by having been surprisingly found that
Hair.
Description of the drawings
Fig. 1 is present invention accumulation transmitance-time plot.
Specific implementation mode
The present invention is described in detail with reference to embodiments, but should not be construed as limiting the invention.
Embodiment 1：
The preparation method of the drug of hair tonic function, its step are as follows：
1) it presses following weight proportion and prepares raw material：Ginseng 6g, cacumen biotae 3g, Radix Astragali 3g, fruit of glossy privet 3g, 2,4- Diaminopyrimidines
Pyridine -3- oxides 2g；
2) ginseng, cacumen biotae, Radix Astragali, the fruit of glossy privet are taken, with 8 times of (weight concentration) ethyl alcohol of weight 75% heating and refluxing extractions 2
Secondary, 2 hours every time, filtering, merging filtrate was simultaneously concentrated into the clear cream that relative density is 1.1-1.2；
3) 2,4- di-amino-pyrimidine -3- oxides are dissolved with 95% ethyl alcohol, obtains solution；
4) solution of the clear cream of step 2), step 3) is merged, and with 5g propylene glycol, 5g glycerine, 0.8g Phenoxyethanols,
0.1g methyl hydroxybenzoates, the mixing of 0.1g hydroxyethyl celluloses, are made solution.
Comparative example
2,4- di-amino-pyrimidine -3- oxides are dissolved with 75% ethyl alcohol, and are added with 1 identical type of embodiment and dosage
Moisturizer, thickener, preservative mixing, 2% 2,4- di-amino-pyrimidine -3- oxide solution agent is made.
Test example
Embodiment 1 and comparative example are subjected to pharmacodynamic experiment.
1 inhibits rat depilation experiment
Experiment material：(1) embodiment of the present invention 1, comparative example, physiological saline, 3% picric acid solution, testosterone propionate note
Penetrate liquid, Spironolactone Tablets.
(2) experimental animal is healthy adult Wistar rats, half male and half female, and 200 ± 20g of weight is tested dynamic by Hubei Province
Object center provides, and animal quality certification number is：SCXK (Hubei Province) 2003-0005.
1.1, experiment packet
Wistar rats are randomly divided into group：1 group of embodiment, comparative example group, blank control group, every group 10, male and female are each
Half, totally 30.
1.2, experimental method
(1) modeling and administration
Each group rat chooses the hair of back 8cm × 5cm areas, with 3% picric acid solution stained yellow with determination
Hair removal section.
Blank control group：Daily gavage gives isometric physiological saline, and isometric physiological saline is subcutaneously injected after neck,
1 times/day；
1 group of embodiment：1 drug of embodiment is given respectively daily to apply outside, and testosterone propionate injection is subcutaneously injected after neck
Liquid 5mg/ (kgd), 1 times/day.
Comparative example group：Comparative example drug is given respectively daily to apply outside, and testosterone propionate injection is subcutaneously injected after neck
5mg/ (kgd), 1 times/day.
(2) index observing
After modeling and administration 4 weeks, the upper metabolic cage of rat is individually raised, rat dyed hair is observed daily and falls off situation
And record, including the yellow trichomadesis quantity of dye and dyeing area's trichomadesis situation.
1.3, experimental result
1 each pharmaceutical intervention of table falls off to Hair of Rats the influence (n=10) of quantity
| Group | Number of cases | Dye area's trichomadesis radical |
| Blank control group | 10 | 39.30±4.32 |
| 1 group of embodiment | 10 | 16.45±4.77** |
| Comparative example group | 10 | 28.10±5.14** |
1 group of embodiment, comparative example group are compared with blank control group, * * P<0.01, there is pole significant difference；1 group of embodiment
Compared with comparative example group, P<0.05, significant difference.
Conclusion：1 group of embodiment and comparative example group cause the rat of epilation to have significantly injection testosterone propionate injection
Anti-avulsion effect, prompt Clinical practice of the present invention can effective hair growth；And 1 group of curative effect of embodiment is better than comparative example group, carries
Let others have a look at ginseng, cacumen biotae, Radix Astragali, the fruit of glossy privet and menthol composition compound pair 2,4- di-amino-pyrimidine -3- oxides have collaboration increase
The effect of effect.
2 Transdermal absorptions are tested
SD rats are taken, using 10%Na2S aqueous solutions take off except back wool, and next day, disconnected neck was put to death, and cut skin of back immediately,
Subcutaneous tissue and fat are rejected, after physiological saline is rinsed well repeatedly, is cut into appropriately sized, inspection skin integrity.Using changing
The rat skin handled well, is fixed on two Room of diffusion cell by good Franz vertical double-chambers diffusion cell (effective area 2.9cm2)
Between, stratum corneum side is to supply chamber.0.5mL is taken to be placed in supply chamber product precision prepared by embodiment 1 and comparative example, to reception
7mL receiving liquids are added in room, receiving liquid is PBS buffer solution (0.01M, pH7.4).Water bath with thermostatic control is set as 32 DEG C, with 150r/
Min magnetic agitations.Respectively at 0.5,1,2,4,6,8,12, take 0.5mL receiving liquids for 24 hours, while supplementing 0.5mL PBS buffer solution,
After 0.45 μm of membrane filtration, 20 μ L sample introductions is taken to measure 2,4- di-amino-pyrimidine -3- oxide peak areas, calculates drug concentration.
HPLC chromatogram condition is as follows：Stationary phase is Ult imate C18 (5m, 4.6 × 250mm), and mobile phase is acetonitrile：
0.55% phosphate aqueous solution (42：58), Detection wavelength 232nm, flow velocity 1.0mL/min, 32 DEG C of column temperature, sample size 10L.
Percutaneous penetration is shown：
2,4- di-amino-pyrimidine -3- oxide solutions reached 42% in 4 hours accumulation transmitances, and with the time
Extend transmitance variation less, 12 hours accumulation transmitances are 51%；
The solution of embodiment 1 is 55% in 4 hours accumulation transmitances, is then gradually increased, and accumulation in 12 hours penetrates
Rate reaches 78%.
As can be seen from the above results, the present invention can not only improve the transdermal suction of 2,4- di-amino-pyrimidine -3- oxides
It produces effects fruit, total transmitance is apparently higher than 2,4- di-amino-pyrimidine -3- oxide solutions, and has slow-releasing and controlled-releasing action, can be with
Given pace slow release is conducive to extend the treatment time of drug to form constant blood concentration in skin.
3 clinical observations
Clinical observation is carried out to the effect of anti-alopecia of the invention, by comparison using Patients Before And After trichomadesis situation,
The effect of alopecia areata areal analysis hair growth accelerating of the present invention.
3.1 auxiliary examination
(1) Endocrinological inspection：Check estrogen level, thyroid function etc..
(2) other：The disease examinations such as Analysis of Nutritive Status, systemic loupus erythematosus, AIDS, syphilis.
3.2 alopecia degree diagnostic criteria：
(1) alopecia area scores：0 point is no alopecia hair loss phenomenon；1 point is alopecia area<6cm2；2 points are alopecia area
6-15cm2；3 points are alopecia area>15cm2。
(2) hair tonic situation scores：0 point is substantially long without kainogenesis；1 point is to grow less new hair；2 points are to grow
Partly new hair；3 points, to grow more new hair, have larger improvement before relatively treating.
3.3 case selection
20~60 years old age was ready to receive 8 weeks curers, and signed and enter clinical research informed consent form person.
3.4 medicine
Experimental group：Embodiment 1
Control group：2.5% minoxidil solution
3.5 curative effect determinate standard
It cures：Hair restores area >=80%, and depilation phenomenon disappears, and hair is obviously grown；
It is effective：80%>Hair restores area >=60%, and depilation phenomenon obviously disappears, and hair starts to grow；
It improves：60%>Hair restores area >=30%, and depilation phenomenon disappears substantially, and hair is slowly grown；
In vain：Hair restores area ＜ 30%, and depilation phenomenon still has.
3.6 clinical groupings and therapy
Enter 60 patients of group case, man 44, female 16；It is about 47 years old average；All patients fill in self questionnaire survey,
And it is diagnosed as hair loss patient through inspections such as head hair features, and exclude because of systemic loupus erythematosus, AIDS and syphilis etc.
Alopecia caused by disease.Case is randomly divided into two groups, and double-blind, pretherapy and post-treatment Self-controlled study are carried out to subject.
Therapy：
Experimental group：The embodiment of the present invention 1, applies at the skin of alopecia, every 2 times.
Control group：Minoxidil solution applies at the skin of alopecia, 2 times a day.
3.7 result
After most of patient smears the embodiment of the present invention 1 in experimental example group case, depilation phenomenon is reduced or is disappeared, on inspection
Hair loss state finds that hair growth is good after treatment before randomized controlled treatment.
Cure rate+obvious effective rate of experimental group is 82.7%, and cure rate+obvious effective rate of control group is 68.1%, and the two is compared
Compared with P<0.01.
Conclusion：The present invention has pole significant difference (P with Western medicine group to the treatment situation of patient's alopecia<0.01)；The present invention 5
The patient of clinical treatment grows black coarse wool hair follow-up 2 years or more between year has 97 without recurrence, therapeutic process do not find allergy,
Phenomena such as abnormal, and Western medicine group only has 15, there is pole significant difference (P between the two<0.01) it is high, to illustrate that the present invention cures.
In addition, have been surprisingly found that there is the white hair blackening of 2 people in experimental group, but control group occurs without this phenomenon, prompts the present invention that may have
The effect of dark hair.
Claims (4)
1. a kind of drug with hair tonic function, it is characterised in that be made of the raw material of following portions by weight：
2-10 parts of ginseng, 1-5 parts of cacumen biotae, 1-5 parts of Radix Astragali,
1-5 parts of the fruit of glossy privet, 2,4- 1-5 parts of di-amino-pyrimidine -3- oxides.
2. the drug with hair tonic function as described in claim 1, it is characterised in that the parts by weight of the raw material are：
4-8 parts of ginseng, 2-4 parts of cacumen biotae, 2-5 parts of Radix Astragali,
2-4 parts of the fruit of glossy privet, 2,4- 2-4 parts of di-amino-pyrimidine -3- oxides.
3. the drug with hair tonic function as described in claim 1, it is characterised in that the parts by weight of the raw material are：
6 parts of ginseng, 3 parts of cacumen biotae, 3 parts of Radix Astragali,
3 parts of the fruit of glossy privet, 2,4- 2 parts of di-amino-pyrimidine -3- oxides.
4. the preparation method of the drug with hair tonic function as described in claim 1-3 any one, it is characterised in that including
Following steps：
1) ginseng, cacumen biotae, Radix Astragali, the fruit of glossy privet are taken, with 75% ethyl alcohol heating and refluxing extraction 2 times, 2 hours every time, filters, merges
Filtrate is simultaneously concentrated into the clear cream that relative density is 1.1-1.2；
2) 2,4- di-amino-pyrimidine -3- oxides are dissolved with 95% ethyl alcohol, obtains solution；
3) solution of the clear cream of step 1), step 2) is merged, and is mixed with moisturizer, thickener, preservative, solution is made
Agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810303491.5A CN108403780A (en) | 2018-04-07 | 2018-04-07 | A kind of drug and preparation method thereof with hair tonic function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810303491.5A CN108403780A (en) | 2018-04-07 | 2018-04-07 | A kind of drug and preparation method thereof with hair tonic function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108403780A true CN108403780A (en) | 2018-08-17 |
Family
ID=63134808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810303491.5A Pending CN108403780A (en) | 2018-04-07 | 2018-04-07 | A kind of drug and preparation method thereof with hair tonic function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108403780A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116870074A (en) * | 2023-08-14 | 2023-10-13 | 江苏春申堂药业有限公司 | Chinese medicinal liniment for preventing hair loss and promoting hair growth, and its preparation method |
| CN116870074B (en) * | 2023-08-14 | 2024-05-17 | 江苏春申堂药业有限公司 | Chinese medicinal liniment for preventing hair loss and promoting hair growth, and its preparation method |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1463693A (en) * | 2002-06-04 | 2003-12-31 | 朱静建 | Hair growing preparation containing compound of Chinese medicine and Western medicine |
| CN101596153A (en) * | 2008-03-28 | 2009-12-09 | 莱雅公司 | Contain 2, the compositions and the purposes of the combination of 4-di-amino-pyrimidine-3-N-oxide and asiaticoside and/or terminoloside |
| CN104398418A (en) * | 2014-11-06 | 2015-03-11 | 陈爱华 | Hair-loss-resistant hair conditioner |
-
2018
- 2018-04-07 CN CN201810303491.5A patent/CN108403780A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1463693A (en) * | 2002-06-04 | 2003-12-31 | 朱静建 | Hair growing preparation containing compound of Chinese medicine and Western medicine |
| CN101596153A (en) * | 2008-03-28 | 2009-12-09 | 莱雅公司 | Contain 2, the compositions and the purposes of the combination of 4-di-amino-pyrimidine-3-N-oxide and asiaticoside and/or terminoloside |
| CN104398418A (en) * | 2014-11-06 | 2015-03-11 | 陈爱华 | Hair-loss-resistant hair conditioner |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116870074A (en) * | 2023-08-14 | 2023-10-13 | 江苏春申堂药业有限公司 | Chinese medicinal liniment for preventing hair loss and promoting hair growth, and its preparation method |
| CN116870074B (en) * | 2023-08-14 | 2024-05-17 | 江苏春申堂药业有限公司 | Chinese medicinal liniment for preventing hair loss and promoting hair growth, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021017846A1 (en) | Enhanced anti-aging cosmetic composition | |
| CN110974891B (en) | Microneedle patch for losing weight and preparation method thereof | |
| KR101394817B1 (en) | Cosmetic Composition Containing Bee Venom or Extracts of the Same | |
| CN109010216A (en) | A kind of whitening cosmetics and preparation method thereof | |
| CN103211959B (en) | Traditional Chinese medicine composition used for tonifying yang and preparation method thereof | |
| CN104622740B (en) | Purposes of the Horse chest Nut P.E in cosmeceutical is prepared | |
| CN106361703A (en) | Finasteride nano-liposome, gel and preparation method thereof | |
| CN104474551B (en) | Melatonin phosphatide complexes, its Percutaneously administrable preparation and preparation method thereof | |
| CN112656703B (en) | Polypeptide flexible liposome and preparation method and application thereof | |
| CN105233248B (en) | Application of the Uropoly acid-peptide in preparation treatment scar drug | |
| CN104800269A (en) | Traditional Chinese medicine external-use cream used for treating psoriasis and preparation method thereof | |
| CN104173607B (en) | It is a kind of to treat pharmaceutical composition of chloasma and preparation method thereof | |
| CN111329837B (en) | Melatonin flexible liposome and preparation method and application thereof | |
| CN111346025B (en) | A liposome capable of improving skin delivery effect of water soluble components, its composition and application in cosmetics | |
| CN103494746B (en) | The novelty teabag of Lignum Santali Albi and a kind of Chinese medicine compound sunscreen composition | |
| KR102130149B1 (en) | Cosmetic composition containing peach gum extract | |
| CN108403780A (en) | A kind of drug and preparation method thereof with hair tonic function | |
| CN104958257B (en) | A kind of Cryptotanshinone skin keratin lipoid body preparation and preparation method thereof | |
| CN101664424B (en) | Application of sesame oil in preparing medicinal preparation for preventing glucocorticoid skin aging-like change | |
| CN105338978A (en) | Composition for promoting collagen production, for promoting elastin production, and/or for promoting keratinocyte migration, and usage therefor | |
| CN111281851A (en) | PH-targeted flexible nanoliposome with acne removing effect and preparation method thereof | |
| CN106031718A (en) | Preparation method of a matrine transdermal agent | |
| CN101518551A (en) | Ganoderma spore oil fat emulsion and quality control method and application thereof | |
| CN114796120B (en) | Anti-hair loss hair-growing liposome and preparation method and application thereof | |
| CN109010395A (en) | A kind of preparation method of the ginkgo emulsifiable paste for soft tissue healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180817 |
|
| RJ01 | Rejection of invention patent application after publication |